These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1098 related articles for article (PubMed ID: 32471382)

  • 1. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
    Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
    Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
    Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
    BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
    Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
    Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.
    Conroy T; Castan F; Etienne PL; Rio E; Mesgouez-Nebout N; Evesque L; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Boilève A; Delaye M; Gourgou S; Pezzella V; Borg C
    Ann Oncol; 2024 Oct; 35(10):873-881. PubMed ID: 38986769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
    Alvarez JA; Shi Q; Dasari A; Garcia-Aguilar J; Sanoff H; George TJ; Hong T; Yothers G; Philip P; Nelson G; Al Baghdadi T; Alese OB; Zambare W; Omer D; Verheij FS; Bercz A; Kim MJ; Buckley J; Williams H; George M; Garcia R; Gallagher P; O'Reilly EM; Meyerhardt JA; Crawley J; Shergill A; Horvat N; Romesser PB; Hall W; Smith JJ
    BMC Cancer; 2024 Jul; 24(1):901. PubMed ID: 39060961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
    Ciseł B; Pietrzak L; Michalski W; Wyrwicz L; Rutkowski A; Kosakowska E; Cencelewicz A; Spałek M; Polkowski W; Jankiewicz M; Styliński R; Bębenek M; Kapturkiewicz B; Maciejczyk A; Sadowski J; Zygulska J; Zegarski W; Jankowski M; Las-Jankowska M; Toczko Z; Żelazowska-Omiotek U; Kępka L; Socha J; Wasilewska-Tesluk E; Markiewicz W; Kładny J; Majewski A; Kapuściński W; Suwiński R; Bujko K;
    Ann Oncol; 2019 Aug; 30(8):1298-1303. PubMed ID: 31192355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol.
    Rouanet P; Castan F; Mazard T; Lemanski C; Nougaret S; Deshayes E; Chalbos P; Gourgou S; Taoum C;
    Colorectal Dis; 2023 Oct; 25(10):2078-2086. PubMed ID: 37697712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma.
    Avila S; Chang GJ; Dasari NA; Smani DA; Das P; Herman JM; Koay E; Koong A; Krishnan S; Minsky BD; Smith GL; Taniguchi C; Taggart MW; Kaur H; Holliday EB
    Clin Colorectal Cancer; 2020 Jun; 19(2):116-122. PubMed ID: 32173279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer.
    Kawai K; Sunami E; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Nozawa H
    Clin Colorectal Cancer; 2018 Sep; 17(3):240-246. PubMed ID: 29934092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.
    Moretto R; Vetere G; Carullo M; Ciracì P; Masi G; Cremolini C
    Cancer Treat Rev; 2024 Nov; 130():102829. PubMed ID: 39305700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial.
    Wang J; Fan J; Li C; Yang L; Wan J; Zhang H; Zhang Z; Zhu J
    Clin Colorectal Cancer; 2020 Jun; 19(2):e58-e69. PubMed ID: 32265117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
    Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.